To maximize the value of medicines while managing limited medical resources, many national and private insurers are applying a Health Technology Assessment (HTA) as a support for the decision-making process. This symposium will cover the use of HTA in three international examples, including discussions of comparative effectiveness analysis, managed entry agreements, and risk share agreements.

Learning Objectives:
Demonstrate guidances of drug access and reimbursement based on the Health Technology Assessment (HTA)
Describe the application of Managed Entry Agreements in NHS conditional reimbursement
Examine a comparative effectiveness analysis of osteoporosis therapies using a real-world national health insurance database Illustrate the impact of orphan drug designation on market access.